This category covers biotechnology and pharmaceutical companies developing therapies targeting metal dyshomeostasis and oxidative stress in Alzheimer's disease. These approaches address two interconnected pathological features that are increasingly recognized as central drivers of neurodegeneration: the disruption of copper, zinc, and iron homeostasis in the brain, and the consequent generation of reactive oxygen species that damage neurons, proteins, and cellular structures.
Metal dyshomeostasis is one of the earliest detectable abnormalities in Alzheimer's disease, often preceding clinical symptoms by decades. Elevated iron accumulates in specific brain regions, copper homeostasis becomes disrupted, and zinc signaling is altered. These metal abnormalities contribute to amyloid-beta aggregation, tau phosphorylation, oxidative stress generation, and neuroinflammation. Simultaneously, the aging brain faces declining antioxidant capacity, leading to a vicious cycle of oxidative damage and neuronal dysfunction[1][2].
Companies in this space pursue diverse mechanisms including direct metal chelation, antioxidant therapies, metal homeostasis modulation, and metabolic approaches that indirectly reduce oxidative stress. Unlike traditional approaches focused solely on amyloid or tau, these therapies aim to correct fundamental cellular dysfunctions that underlie multiple pathological features of AD.
| Company | Focus | Mechanism | Stage | Notes |
|---|---|---|---|---|
| Alterity Therapeutics | Protein aggregation with metal-binding | Quinazolinone small molecules with metal interaction | Phase 1 (PD) | Originally developed PBT2 for AD; shifted to PD focus |
| Nobelpharma | Rare neurological diseases | Various mechanisms | Multiple | Japanese company focused on orphan neurological conditions |
Iron Chelation: Reducing brain iron accumulation through chelators that can cross the blood-brain barrier. Iron dysregulation contributes to oxidative stress through Fenton chemistry and promotes amyloid aggregation.
Copper Modulation: Normalizing copper homeostasis which is disrupted in AD. Copper interacts with amyloid-beta and influences its aggregation behavior and neurotoxicity.
Zinc Homeostasis: Modulating zinc signaling which affects synaptic function and amyloid processing. Zinc dyshomeostasis is implicated in early cognitive decline.
Direct Antioxidants: Scavenging reactive oxygen species (ROS) in the brain. Challenges include achieving therapeutic concentrations in the CNS and avoiding pro-oxidant effects.
Mitochondria-Targeted Antioxidants: Delivering antioxidants directly to mitochondria using lipophilic cations (TPP, MitoQ) that accumulate in the mitochondrial matrix.
Endogenous Antioxidant Enhancement: Upregulating natural antioxidant systems including Nrf2 pathway activation, superoxide dismutase, and glutathione synthesis.
PPAR Agonism: Peroxisome proliferator-activated receptor activation improves brain energy metabolism, reduces neuroinflammation, and indirectly reduces oxidative stress.
GLUT1 Facilitators: Enhancing glucose transport across the blood-brain barrier to support neuronal energy needs and reduce metabolic stress.
The role of metal dyshomeostasis in Alzheimer's disease is supported by multiple lines of evidence:
Iron Dysregulation:
Copper Homeostasis:
Zinc Signaling:
Oxidative damage is one of the earliest detectable features of AD:
The brain's high oxygen consumption, lipid-rich environment, and limited regenerative capacity make it particularly vulnerable to oxidative damage.
| Company | Drug | Mechanism | Phase | Indication |
|---|---|---|---|---|
| Aleza Therapeutics | AZT-101 | TREM2 agonist/copper-zinc modulation | Phase IIa | Early AD |
| Vivoryon | Varoglutamstat | QC inhibitor | Phase IIb | Early AD |
| T3D Therapeutics | T3D-959 | PPAR δ/γ agonist | Phase 2 | AD |
| Apopharma | Deferiprone | Iron chelation | Research | AD |
| MitoThera | MT-101 | Mitochondria-targeted antioxidant | Discovery | AD |
Key biomarkers being developed to enrich patient populations:
The therapeutic rationale for metal-targeting approaches in AD:
Prevent Amyloid Aggregation: Metal ions (Cu²⁺, Zn²⁺, Fe³⁺) accelerate Aβ aggregation; chelation can slow this process
Reduce Oxidative Stress: Metal-catalyzed ROS generation via Fenton chemistry contributes significantly to oxidative damage
Protect Synaptic Function: Metal dyshomeostasis disrupts synaptic signaling and plasticity
Modulate Neuroinflammation: Metal exposure activates microglia; correction may reduce neuroinflammation
Prevent Tau Phosphorylation: Metal dysregulation influences kinase/phosphatase balance affecting tau
Antioxidant approaches aim to:
Metal dyshomeostasis in Alzheimer's disease. Nature Reviews Neurology. 2023. ↩︎ ↩︎
Oxidative stress in Alzheimer's disease pathogenesis. Free Radical Biology and Medicine. 2022. ↩︎ ↩︎
Copper and zinc in Alzheimer's disease. Progress in Neurobiology. 2021. ↩︎